Exubera’s change in control

Pfizer and Sanofi-Aventis are in discussions concerning their partnership for Exubera following a judge's ruling that a "change of control" has occurred in the companies' agreement, Pfizer said during its quarterly earnings call July 20. Pfizer said it now has rights to Exubera under the court's ruling and pursuant to a 1998 agreement between Pfizer and Aventis governing co-marketing of the inhaled insulin. Following Sanofi's acquisition of Aventis in August 2004, Pfizer sued the company in the U.S. and Germany seeking to enforce change of control provisions for Exubera (1"The Pink Sheet" Oct. 25, 2004, p. 17). The Exubera NDA will be reviewed by FDA's Endocrinologic & Metabolic Drugs Advisory Committee on Sept. 8...